Latest News for Cyberdyne Stock (OTC:CYBQF)

Cyberdyne Inc is a Japanese based company engaged in the research and development of medical welfare equipment and systems. It offers equipment and systems for rehabilitation support, body function support for elderly and disabled people, rescue support in disaster sites, entertainments, and heavy labor support in factories. Its products include Hybrid Assistive Limb (HAL) for the lower limb, single joint, lumbar, Table Interface and Cleaning Robots. In addition, it also offers services in respect to medical service and non-medical service which includes HAL therapy under medical service, and Hal fit and Robo care service under non-medical service.

News

Intraday Update

Markets

Movers

Trading Ideas

AGEEF

AKTAF

BCOV

BNNLF

BSAC

BTTR

CASI

CCOZF

CEIX

CGAAY

CGCO

CGRA

CJPRY

CLSH

CTRM

CWBHF

CYBQF

DLUEY

DNTUY

ECOL

EJPRY

ERMAY

EUOT

FEIM

GDNEF

GFGSF

GGLT

GNMK

GPHBF

GSUM

GWRRF

HBCYF

HBRM

HZNFF

ITCB

JAPAY

JAPSY

JGFCF

KMTUY

KPCPY

LFAP

LIVE

LNTH

LRSNF

MALJF

MBGRF

MFMLF

MOBQ

MSPC

MZDAY

NDBKY

NGVC

NINOY

NODK

OSUR

PDPYF

PLPRF

PETROTEQ ENERGY INC by Petroteq Energy Inc.

PQEFF

QEGY

RCON

RDS-B

RMTD

RSSV

RWLK

RYKKY

SCIE

SHMDF

SRDX

STAY

TARO

TBLMY

TOPS

TOSYY

TRNX

TVTY

UBQU

UBSI

UNEQ

USGDF

Stocks That Hit 52-Week Lows On Thursday

APRN

APTS

BHAT

BLONF

BLUBF

CBGZF

CBYDF

CEBUY

CIDM

CONN

CORV

ECCI

EDRY

ELGX

FITX

FLWPF

GGTTF

GMLP

GOVXD

GTEC

HCMC

HESG

HMNY

IMPJY

KEQU

KHRIF

KKPNY

KRKR

LKREF

LNGLF

LNGLY

MFGP

MGAWY

MICWF

MITO

MPJFF

MTSC

MXSG

MYDX

NAKD

NMHLY

NSANY

NSPX

ORAN

OWPC

OYIEF

PMTYF

PNWRF

POEFF

PURA

PYRNF

RGSE

RKGXF

RYDBF

SCFFF

SGMD

SIML

SOCLF

SOHFF

STWC

TOIPF

TXHG

USAK

WDHR

WNWG

WTSHF

Stocks That Hit 52-Week Lows On Tuesday

Cyberdyne Inc

<p>Argus Research  analyst John Eade   maintains Owens-Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OC#NYSE">OC</a>) with a Buy and raises the price target from $175 to $182.</p>


Price Target

Analyst Ratings

Argus Research Maintains Buy on Owens-Corning, Raises Price Target to $182

<p>The hastily-scribbled &#8220;Buy <strong>Bitcoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)&#8221; sign that went viral during a Congressional hearing in 2017 has become a million-dollar collector&#8217;s item.</p>
<p><strong>What Happened</strong>: The now-iconic sign, a symbol of early Bitcoin enthusiasm, sold for a staggering $1.027 million at auction, Bloomberg <a href="https://www.bloomberg.com/news/articles/2024-04-24/-buy-bitcoin-sign-shown-behind-yellen-sells-for-1-million-at-auction?embedded-checkout=true">reported</a>.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">The famous &quot;Buy Bitcoin&quot; sign was just sold for more than $1 Million today.<br /><br />The sign was shown during then-FED chair Janet Yellen&#39;s Congressional testimony back in July 2017. <a href="https://t.co/qGtWCJRNM9">pic.twitter.com/qGtWCJRNM9</a></p>
<p>&mdash; Lark Davis (@TheCryptoLark) <a href="https://twitter.com/TheCryptoLark/status/1783473604715327645?ref_src=twsrc%5Etfw">April 25, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>The winning bid, placed anonymously, came in at 16 bitcoin. </p>
<p>There was a brief moment of confusion during the final minutes when a technical error displayed a much higher bid, but the final price settled at the million mark.</p>
<p>The seller was <strong>Christian Langalis</strong>, the then 22-year-old intern who impulsively created the sign and held it up behind then-Federal Reserve Chair <strong>Janet Yellen</strong> during her testimony. </p>
<p>Langalis was promptly escorted out of the hearing room, but his message clearly resonated with the crypto community.</p>
<p>This sky-high auction price reflects the incredible rise of Bitcoin itself. </p>
<p>Since 2017, the value of Bitcoin has skyrocketed from around $2,300 to a record high of nearly $74,000 earlier this year. </p>
<p>This surge has attracted major financial institutions like <strong>Fidelity </strong>and <strong>BlackRock Inc.</strong>, along with a renewed wave of interest from retail investors.</p>
<p>As a result, early Bitcoin artifacts like the &#8220;Buy Bitcoin&#8221; sign are experiencing a resurgence in popularity. </p>
<p>This unassuming legal pad, once a bargain at $8.99 for a three-pack, now stands as a testament to the transformative power of cryptocurrency.</p>
<p><figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></a></figure></p>
<p><em>Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38412858/trumps-crypto-portfolio-rebounds-with-1m-weekly-profit-which-crazy-new-currencies-does-he-">Trump&#8217;s Crypto Portfolio Rebounds With $1M Weekly Profit: Which &#8216;Crazy New Currencies&#8217; Does He Hold?</a></em></p>
<p><strong>Beyond The Bitcoin Bonanza</strong></p>
<p>The story doesn&#8217;t end with Bitcoin. </p>
<p>This week also saw <a href="https://twitter.com/RDToTheMoon/status/1783166550247194801">another</a> internet meme go up for auction.</p>
<p>This image, featuring a man yelling into a woman&#8217;s ear while looking at another woman, has been widely shared and parodied online. </p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">&#x1f6a8;AUCTION ALERT&#x1f6a8;<br /><br />The popular Nightclub meme photo of a man shouting into a woman&#39;s ear at a club in Edinburgh, Scotland, has gained widespread popularity since its creation in 2018. It has appeared in various media and has been shared by figures like Elon Musk. <br /><br />Today, it&#39;s… <a href="https://t.co/2CNt7pSCnp">pic.twitter.com/2CNt7pSCnp</a></p>
<p>&mdash; Rob &#x7C; Foundation (@RDToTheMoon) <a href="https://twitter.com/RDToTheMoon/status/1783166550247194801?ref_src=twsrc%5Etfw">April 24, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>Currently, the highest bid for this meme sits at 15 <strong>Ethereum </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>).</p>
<p>These high-profile auctions highlight the growing value of digital assets, both established like Bitcoin and more whimsical like viral memes.</p>
<p><strong>The Future Of Digital Assets: A Discussion At Benzinga&#8217;s Upcoming Event</strong></p>
<p>These sales are just two examples of how digital assets are reshaping the way we interact with and value online content.</p>
<p>The Benzinga <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event, scheduled for Nov. 19, will bring together industry leaders, analysts, and investors to<a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38404202/why-sec-delays-put-the-may-ethereum-etf-deadline-in-doubt"> explore these critical trends.</a></p>
<p><em>Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38408395/why-is-mog-crypto-coin-going-up-trader-sees-billions-as-price-target">Why Is MOG Crypto Coin Going Up? Trader Sees &#8216;Billions&#8217; As Price Target</a></em></p>
<p><em>Image: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

This Famous 'Buy Bitcoin' Sign Netted An Intern $1M

<p>Shares of <strong>Asbury Automotive Group Inc </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABG#NYSE">ABG</a>) are trading at $213.99 each; that&#8217;s down by <a href="https://www.benzinga.com/movers" target="_blank" rel="noreferrer noopener">more than 3.4% at last check Thursday.</a></p>
<p>The Duluth, Georgia-based company reported first-quarter earnings per share of $7.21, missing the street view of $7.76 due to a <a href="https://www.benzinga.com/pressreleases/24/04/b38426134/asbury-automotive-group-reports-record-4-2-billion-in-revenue" target="_blank" rel="noreferrer noopener">tight inventory market and volume challenges. </a></p>
<p>Quarterly sales of $4.201 billion missed the street view of $4.264 billion. Revenue, however, <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">increased 17% year over year.</a> Gross profit increased 8% year-over-year to $750 million, while gross margin decreased 158 bps to 17.9%.</p>
<p>&#8220;We delivered on our ongoing commitment to profitably grow same store preowned volume by retailing over 2,700 more units sequentially, even in a tight inventory market, and new vehicle profits performed well against brand mix driven volume challenges,&#8221; said Asbury CEO <strong>David Hult</strong>.</p>
<p>Asbury&nbsp;said new vehicle unit volume increased by 18%, new vehicle revenue increased by 17%, while new vehicle gross profit decreased by 9%.</p>
<p>Same-store revenue of $3.5 billion decreased 1% year over year, while gross margin&nbsp;decreased&nbsp;136 bps to 18.1%.</p>
<p>As of March 31, 2024, the company had cash and floor plan offset accounts of $225 million.</p>
<p>The company repurchased approximately 240,000 shares for $50 million during the first quarter of 2024.&nbsp;</p>
<p>&#8220;Our results demonstrate how our strategic investments have enabled us to deliver strong results despite&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">challenging market conditions,&#8221; the CEO added.</a></p>
<p><strong>Share Repurchases</strong></p>
<p>The company repurchased approximately 240,000 shares for $50 million during the first quarter&nbsp;2024.&nbsp;</p>
<p>As of March 31, Asbury&nbsp;had $153 million remaining on its share repurchase authorization.</p>
<p><strong>Price Action:&nbsp;</strong>ABG shares are trading lower by 3.55% to $213.66 at last check Thursday.</p>
<p><em>Now Read: </em></p>


Earnings

Equities

General

Asbury Automotive Is Trading Lower On Heels Of Q1 Earnings Report

<p>PennyMac Financial Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFSI#NYSE">PFSI</a>) reported quarterly earnings of $2.48 per share which beat the analyst consensus estimate of $2.31 by 7.36 percent. The company reported quarterly sales of $305.660 million which missed the analyst consensus estimate of $432.416 million by 29.31 percent. This is a 0.92 percent increase over sales of $302.862 million the same period last year.</p>


PFSI

On Wednesday April 24, 2024 PennyMac Financial Servs Reported Q1 2024 Adj EPS $2.48 Beats $2.31 Estimate, Sales $305.660M Miss $432.416M Estimate

<p>In the latest quarter, 5 analysts provided ratings for Alexandria Real Estate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $138.4, with a high estimate of $140.00 and a low estimate of $132.00. Witnessing a positive shift, the current average has risen by 1.02% from the previous average price target of $137.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714060884_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Alexandria Real Estate. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$132.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Richard Anderson</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$140.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Anderson</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$140.00</td>
<td>-</td>
</tr>
<tr>
<td>Aaron Hecht</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$140.00</td>
<td>-</td>
</tr>
<tr>
<td>Omotayo Okusanya</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$140.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Alexandria Real Estate. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Alexandria Real Estate compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Alexandria Real Estate's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Alexandria Real Estate's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ARE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Alexandria Real Estate analyst ratings.</strong></a></p>
<h2>Get to Know Alexandria Real Estate Better</h2>
<p>Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.</p>
<h3>Understanding the Numbers: Alexandria Real Estate's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Alexandria Real Estate showcased positive performance, achieving a revenue growth rate of <strong>9.75%</strong> as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>21.7%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>0.9%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Alexandria Real Estate's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.45%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.68</strong>.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


The Analyst Landscape: 5 Takes On Alexandria Real Estate

WIIM

WEX shares are trading lower after the company reported worse-than-expected Q1 financial results and issued Q2 adjusted EPS guidance below estimates.

<p>In the latest quarter, 7 analysts provided ratings for MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $1740.0, a high estimate of $1875.00, and a low estimate of $1450.00. This current average reflects an increase of 57.47% from the previous average price target of $1105.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714060874_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive MicroStrategy. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark Palmer</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$1875.00</td>
<td>-</td>
</tr>
<tr>
<td>Mark Palmer</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$1875.00</td>
<td>$990.00</td>
</tr>
<tr>
<td>Andrew Harte</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$1800.00</td>
<td>$780.00</td>
</tr>
<tr>
<td>Joseph Vafi</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$1810.00</td>
<td>-</td>
</tr>
<tr>
<td>Lance Vitanza</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$1450.00</td>
<td>$1560.00</td>
</tr>
<tr>
<td>Lance Vitanza</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1560.00</td>
<td>$1220.00</td>
</tr>
<tr>
<td>Joseph Vafi</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$1810.00</td>
<td>$975.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to MicroStrategy. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of MicroStrategy compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of MicroStrategy's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into MicroStrategy's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MSTR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on MicroStrategy analyst ratings.</strong></a></p>
<h2>Discovering MicroStrategy: A Closer Look</h2>
<p>MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web; MicroStrategy Server, which provides analytical processing and job management. The company's reportable operating segment is engaged in the design, development, marketing, and sales of its software platform through licensing arrangements and cloud-based subscriptions and related services.</p>
<h3>Unraveling the Financial Story of MicroStrategy</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, MicroStrategy faced challenges, resulting in a decline of approximately <strong>-6.09%</strong> in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> MicroStrategy's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>71.6%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> MicroStrategy's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>5.93%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> MicroStrategy's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>2.19%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> MicroStrategy's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>1.04</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


MSTR

Where MicroStrategy Stands With Analysts

<p>9 analysts have expressed a variety of opinions on Equity Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQR#NYSE">EQR</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $66.33, a high estimate of $70.00, and a low estimate of $61.00. This current average reflects an increase of 0.94% from the previous average price target of $65.71. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714060865_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The perception of Equity Residential by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>John Kim</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Michael Lewis</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$67.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Alexander Goldfarb</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$62.00</td>
<td>-</td>
</tr>
<tr>
<td>Vikram Malhorta</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$61.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Adam Kramer</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$64.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Chandni Luthra</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Anthony Powell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$67.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Brad Heffern</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$66.00</td>
<td>$65.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Equity Residential. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Equity Residential compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Equity Residential's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Equity Residential's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EQR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Equity Residential analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Equity Residential</h2>
<p>Equity Residential owns a portfolio of 302 apartment communities with around 80,000 units and is developing two additional properties with 537 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.</p>
<h3>Financial Insights: Equity Residential</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Equity Residential's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>3.97%</strong> as of 31 December, 2023, showcasing a substantial increase in top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Equity Residential's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>42.74%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Equity Residential's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>2.82%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Equity Residential's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.55%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.7</strong>.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Beyond The Numbers: 9 Analysts Discuss Equity Residential Stock

<p>In the preceding three months, 8 analysts have released ratings for Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Biomarin Pharmaceutical, revealing an average target of $100.88, a high estimate of $110.00, and a low estimate of $85.00. This current average has decreased by 5.05% from the previous average price target of $106.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714060857_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The standing of Biomarin Pharmaceutical among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$85.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Hold</td>
<td>$91.00</td>
<td>-</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$107.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$104.00</td>
<td>$127.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Biomarin Pharmaceutical. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Biomarin Pharmaceutical compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Biomarin Pharmaceutical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Biomarin Pharmaceutical's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BMRN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Biomarin Pharmaceutical analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Biomarin Pharmaceutical</h2>
<p>BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.</p>
<h3>Biomarin Pharmaceutical: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Biomarin Pharmaceutical's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of <strong>20.22%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Biomarin Pharmaceutical's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>3.15%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Biomarin Pharmaceutical's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>0.41%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Biomarin Pharmaceutical's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.3%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Biomarin Pharmaceutical's debt-to-equity ratio is below the industry average. With a ratio of <b>0.22</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BMRN

Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (8 Ratings)

<p>Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on Owens-Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OC#NYSE">OC</a>) in the last three months.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Owens-Corning and provided 12-month price targets. The average target is $168.7, accompanied by a high estimate of $192.00 and a low estimate of $145.00. Marking an increase of 4.39%, the current average surpasses the previous average price target of $161.60. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714060844_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The standing of Owens-Corning among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Lovallo</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$192.00</td>
<td>$169.00</td>
</tr>
<tr>
<td>Stephen Kim</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$172.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$169.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Garik Shmois</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$188.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Michael Rehaut</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$163.00</td>
<td>$164.00</td>
</tr>
<tr>
<td>John Lovallo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$169.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Mike Dahl</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Keith Hughes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$145.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Stephen Kim</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$154.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Matthew Bouley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$160.00</td>
<td>$176.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Owens-Corning. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Owens-Corning compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Owens-Corning's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Owens-Corning's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/OC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Owens-Corning analyst ratings.</strong></a></p>
<h2>All You Need to Know About Owens-Corning</h2>
<p>Owens-Corning Inc is a manufacturer of glass fiber utilized in composites and building materials. It has an integrated business model with three reportable segments: Composites, Insulation, and Roofing. It generates maximum revenue from the Roofing segment. Its Roofing segment laminate and strip asphalt roofing shingles, roofing components, synthetic packaging materials, and oxidized asphalt. It meets the growing demand for longer-lasting, aesthetically attractive laminate products with modest capital investment. Geographically the company generates the majority of its revenue from the United States.</p>
<h3>Owens-Corning: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Revenue Growth:</strong> Owens-Corning's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately <strong>0.83%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.</p>
<p><strong>Net Margin:</strong> Owens-Corning's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>5.69%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Owens-Corning's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>2.55%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Owens-Corning's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>1.17%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.63</strong>, Owens-Corning adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Expert Ratings For Owens-Corning

<p>RBC Capital  analyst Mark Dwelle   maintains Goosehead Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSHD#NASDAQ">GSHD</a>) with a Outperform and lowers the price target from $88 to $80.</p>


GSHD

RBC Capital Maintains Outperform on Goosehead Insurance, Lowers Price Target to $80

<p>In the latest quarter, 10 analysts provided ratings for Fortive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Fortive, revealing an average target of $88.6, a high estimate of $101.00, and a low estimate of $80.00. This current average has increased by 4.1% from the previous average price target of $85.11. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714060817_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>A clear picture of Fortive's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$83.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$84.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$101.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$97.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$99.00</td>
<td>-</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$80.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Brett Linzey</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$80.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$85.00</td>
<td>$79.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Fortive. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Fortive compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Fortive's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Fortive's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FTV/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Fortive analyst ratings.</strong></a></p>
<h2>All You Need to Know About Fortive</h2>
<p>Fortive is a diversified industrial technology firm with a broad portfolio of mission-critical products and services that include field solutions, product realization, health, and sensing technologies. The company serves a wide range of end markets, including manufacturing, utilities, medical, and electronics. Fortive generated roughly $6.1 billion in revenue in 2023.</p>
<h3>Understanding the Numbers: Fortive's Finances</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Fortive's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>3.52%</strong> as of 31 December, 2023, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Fortive's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>16.75%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Fortive's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>2.6%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Fortive's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>1.63%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Fortive's debt-to-equity ratio is below the industry average at <strong>0.37</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


10 Analysts Have This To Say About Fortive

<p>Raymond James  analyst Buck Horne   reiterates PulteGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>) with a Outperform and raises the price target from $120 to $135.</p>


Reiteration

Raymond James Reiterates Outperform on PulteGroup, Raises Price Target to $135

AMBP

Ardagh Metal Packaging shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results.

IPOs

LOAR

Loar Holdings Shares Open For Trade At $45/Share; IPO Priced At $28/Share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Latest News for Cyberdyne Stock (OTC:CYBQF)

Thursday, February 20, 2020

Tuesday, February 04, 2020